Foamix于2003年1月19号在以色列成立。该公司是一家临床阶段制药公司专注于开发和商业化公司专有的泡沫米诺环素治疗痤疮,脓疱疮等皮肤状况。该公司的主导候选产品,fmx101为中度至重...查看全文
牛唐2018-07-28 22:07
$Foamix(FOMX)$ FMX101是外用的minocyline,用于治疗痤疮,预计今年下半年或明年上半年申报NDA,如果获批的话,将是首个获批的米诺环素外用药查看全文
$Foamix(FOMX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-018198 Size: 14 KB 网页链接
$Foamix(FOMX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-018199 Size: 19 KB 网页链接
$Foamix(FOMX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-018202 Size: 22 KB 网页链接
$Foamix(FOMX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-018204 Size: 15 KB 网页链接
$Foamix(FOMX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-018190 Size: 8 KB 网页链接
$Foamix(FOMX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-018192 Size: 18 KB 网页链接
$Foamix(FOMX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-018193 Size: 9 KB 网页链接
$Foamix(FOMX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-018194 Size: 29 KB 网页链接
$Foamix(FOMX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-018195 Size: 33 KB 网页链接
$Foamix(FOMX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-018196 Size: 17 KB 网页链接